Entrada Therapeutics, Inc.
General ticker "TRDA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $382.4M (TTM average)
Entrada Therapeutics, Inc. follows the US Stock Market performance with the rate: 6.1%.
Estimated limits based on current volatility of 3.6%: low 10.39$, high 11.15$
Factors to consider:
- Total employees count: 183 (+15.1%) as of 2024
- Top business risk factors: Operational and conduct risks, Limited operating history, Therapeutic candidate dependency, Early stage company risks, Market competition
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [10.43$, 20.71$]
- 2025-12-31 to 2026-12-31 estimated range: [9.08$, 18.42$]
Financial Metrics affecting the TRDA estimates:
- Positive: with PPE of 9.1 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 22.30 > 18.33
- Negative: Operating cash flow per share per price, % of -6.39 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Positive: Return on assets ratio (scaled to [-100,100]) of 11.09 > 6.04
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: -4.41 < Investing cash flow per share per price, % of -4.28
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Shareholder equity ratio, % of 81.45 > 64.17
- Negative: Industry earnings per price (median), % of -16.21 <= 0
- Negative: Inventory ratio change, % of 44.54 > 0.82
Short-term TRDA quotes
Long-term TRDA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $129.01MM | $210.78MM |
| Operating Expenses | $97.25MM | $132.18MM | $163.77MM |
| Operating Income | $-97.25MM | $-3.16MM | $47.01MM |
| Non-Operating Income | $5.26MM | $15.22MM | $19.47MM |
| R&D Expense | $66.61MM | $99.88MM | $125.31MM |
| Income(Loss) | $-91.98MM | $12.06MM | $66.48MM |
| Taxes | $0.00MM | $18.74MM | $0.86MM |
| Profit(Loss)* | $-91.98MM | $-6.68MM | $65.63MM |
| Stockholders Equity | $212.55MM | $242.36MM | $428.68MM |
| Assets | $252.06MM | $469.19MM | $526.32MM |
| Operating Cash Flow | $-93.79MM | $139.80MM | $-41.56MM |
| Capital expenditure | $2.89MM | $5.61MM | $3.16MM |
| Investing Cash Flow | $-148.65MM | $-138.40MM | $-27.80MM |
| Financing Cash Flow | $0.48MM | $21.04MM | $102.96MM |
| Earnings Per Share** | $-2.94 | $-0.20 | $1.76 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.